68/100BBristol-Myers Squibb stock forecast 2026–2030What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for Bristol-Myers Squibb is 66.14, 4.3% above the current price of 63.43. Their targets range from 41.00 to 78.00.
Of the 16 firms that rated Bristol-Myers Squibb in the past 12 months, 7 rate it buy or strong buy, 8 hold and 1 sell or strong sell (each firm at its latest rating): a Hold consensus.
Analysts' 1-year price targets range from 41.00 to 78.00, with an average of 66.14.
| Buy | 7 | |
| Hold | 8 | |
| Sell | 1 |
12-month price target
| Highest target | 78.00 |
| Average target | 66.14 |
| Lowest target | 41.00 |
| Current price | 63.43 |
Bristol-Myers Squibb price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their Bristol-Myers Squibb price target and rating?
How analysts rate Bristol-Myers Squibb, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
7 of 16 firms rate it buy now, against 4 of 11 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
Bristol-Myers Squibb analyst upgrades, downgrades and price targets
The latest rating change came on 5 October 2026, when Leerink Partners downgraded Bristol-Myers Squibb from Outperform to Market Perform. Its price target is 59.00, from 60.00. The most recent new target came from Bank of America Securities on 30 October 2026: 67.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 30 Oct 2026 | Bank of America Securities Jason Gerberry | — | 67.00 | — | 62.48 |
| 30 Oct 2026 | Truist Financial Srikripa Devarakonda | — | 65.00 → 70.00 | +7.7% | 61.39 |
| 26 Oct 2026 | Piper Sandler | Reiterated · Overweight | 82.00 → 78.00 | -4.9% | 61.48 |
| 12 Oct 2026 | Jefferies Akash Tewari | — | 76.00 | — | 57.58 |
| 8 Oct 2026 | Cantor Fitzgerald Carter Gould | Reiterated · Neutral | 59.00 → 53.00 | -10.2% | 59.70 |
| 7 Oct 2026 | Morgan Stanley Terence Flynn | Reiterated · Underweight | 40.00 → 41.00 | +2.5% | 59.70 |
| 5 Oct 2026 | Leerink Partners | Downgraded · Outperform → Market Perform | 60.00 → 59.00 | -1.7% | 59.02 |
| 23 Sept 2026 | Goldman Sachs Asad Haider | — | 63.00 | — | 62.25 |
| 16 Sept 2026 | Piper Sandler | Reiterated · Overweight | 75.00 → 82.00 | +9.3% | 63.73 |
| 10 Sept 2026 | HSBC | Reiterated · Hold | 53.00 → 65.00 | +22.6% | 64.41 |
| 5 Aug 2026 | Roth Capital | — | 75.00 | — | 63.47 |
| 5 Aug 2026 | Argus Research Jasper Hellweg | Upgraded · Hold → Buy | 75.00 | — | 65.89 |
| 4 Aug 2026 | RBC Capital Trung Huynh | — | 60.00 → 64.00 | +6.7% | 64.73 |
| 31 Jul 2026 | Cantor Fitzgerald Carter Gould | Reiterated · Neutral | 54.00 → 59.00 | +9.3% | 63.67 |
| 31 Jul 2026 | Guggenheim Seamus Fernandez | Reiterated · Buy | 72.00 → 75.00 | +4.2% | 64.86 |
| 31 Jul 2026 | Wells Fargo | Reiterated · Equal Weight | 60.00 → 65.00 | +8.3% | 64.86 |
| 8 Apr 2026 | Cantor Fitzgerald | Reiterated · Neutral | 54.00 | — | 59.20 |
| 6 Mar 2026 | UBS Michael Yee | — | 65.00 → 70.00 | +7.7% | 59.79 |
| 24 Feb 2026 | RBC Capital Trung Huynh | — | 60.00 | — | 61.60 |
| 23 Feb 2026 | Piper Sandler | Reiterated · Overweight | 66.00 → 75.00 | +13.6% | 60.66 |
| 19 Feb 2026 | Barclays | — | 75.00 | — | 60.30 |
| 6 Feb 2026 | Morgan Stanley Terence Flynn | — | 37.00 → 40.00 | +8.1% | 61.86 |
| 6 Feb 2026 | Guggenheim | Reiterated · Buy | 62.00 → 72.00 | +16.1% | 59.52 |
| 6 Feb 2026 | Wells Fargo Mohit Bansal | Reiterated · Equal Weight | 60.00 | — | 59.52 |
| 28 Jan 2026 | Piper Sandler | Reiterated · Overweight | 65.00 → 66.00 | +1.5% | 55.56 |
| 13 Jan 2026 | Leerink Partners David Risinger | Reiterated · Outperform | 60.00 | — | 56.39 |
| 9 Jan 2026 | Scotiabank Louise Chen | Reiterated · Sector Perform | 53.00 → 60.00 | +13.2% | 55.87 |
| 7 Jan 2026 | UBS | Upgraded · Neutral → Buy | 65.00 | — | 56.42 |
| 15 Dec 2025 | B of A Securities | Upgraded · Neutral → Buy | — | — | — |
| 12 Dec 2025 | Morgan Stanley | Reiterated · Underweight | 37.00 | — | 52.63 |
| 12 Dec 2025 | Guggenheim | Upgraded · Neutral → Buy | 62.00 | — | 51.20 |
| 10 Dec 2025 | HSBC | — | 53.00 | — | 50.68 |
| 4 Dec 2025 | Scotiabank Louis Chen | Reiterated · Sector Perform | 53.00 | — | 50.96 |
| 3 Dec 2025 | Truist Financial Srikripa Devarakonda | — | 84.00 → 65.00 | -22.6% | 50.98 |
Bristol-Myers Squibb EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Revenue
EPS
Does Bristol-Myers Squibb beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 16.7% off the result, either way, and their revenue estimate 4.9%, over the last 12 quarters.
- EPS beats
- 92 / 136
- Revenue beats
- 86 / 119
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +16.7%
- Since
- January 1993
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 29 Oct 2026 | 1.10 | 1.35 | +22.7% | 12.72B | 13.07B | +2.7% |
| Q2 FY2026 | 30 Jul 2026 | 1.60 | 2.04 | +27.5% | 11.74B | 12.97B | +10.5% |
| Q1 FY2026 | 30 Apr 2026 | 1.42 | 1.58 | +11.3% | 10.93B | 11.49B | +5.1% |
| Q4 FY2025 | 5 Feb 2026 | 1.23 | 1.26 | +2.4% | 12.28B | 12.50B | +1.8% |
| Q3 FY2025 | 30 Oct 2025 | 1.52 | 1.63 | +7.2% | 11.85B | 12.22B | +3.1% |
| Q2 FY2025 | 31 Jul 2025 | 1.09 | 1.46 | +33.9% | 11.44B | 12.27B | +7.2% |
| Q1 FY2025 | 24 Apr 2025 | 1.49 | 1.80 | +20.8% | 10.70B | 11.20B | +4.7% |
| Q4 FY2024 | 6 Feb 2025 | 1.47 | 1.67 | +13.6% | 11.57B | 12.34B | +6.7% |
| Q3 FY2024 | 31 Oct 2024 | 1.49 | 1.80 | +20.8% | 11.26B | 11.89B | +5.6% |
| Q2 FY2024 | 26 Jul 2024 | 1.62 | 2.07 | +27.8% | 11.54B | 12.20B | +5.7% |
| Q1 FY2024 | 25 Apr 2024 | -4.41 | -4.40 | +0.2% | 11.48B | 11.87B | +3.3% |
| Q4 FY2023 | 2 Feb 2024 | 1.52 | 1.70 | +11.8% | 11.19B | 11.48B | +2.5% |
Bristol-Myers Squibb stock price 2026–2030: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
If Bristol-Myers Squibb's earnings keep growing at the -4.9% a year analysts expect to FY2028, it would earn about 4.79 a share in FY2030. At the P/E it has traded at over the last five years (13.2 to 24.2) that is 63.38 to 116.11 a share, or 83.27 at its average P/E of 17.4. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2026 | 6.44 | 85.21 | 111.95 | 156.11 |
| FY2027 | 6.70 | 88.59 | 116.39 | 162.29 |
| FY2028 | 5.30 | 70.03 | 92.00 | 128.29 |
| FY2029 (extrapolated) | 5.04 | 66.62 | 87.53 | 122.05 |
| FY2030 (extrapolated) | 4.79 | 63.38 | 83.27 | 116.11 |
Each year's EPS is the analysts' consensus to FY2028; the years after grow -4.9% a year (the analysts' growth, at most 15%). Bear, base and bull apply the lowest, average and highest P/E of today and the last five fiscal year ends, leaving out any above 60, the mark of a year of collapsed earnings (13.2, 17.4, 24.2).
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 35.760 | 71.4258Price 35.76193 | +99.7% | |
| 29.080 | 56.2434Price 29.0896 | +93.4% | |
| 240.360 | 464.26205Price 240.36627 | +93.2% | |
| 202.040 | 384.58163Price 202.042,644 | +90.3% | |
| 161.340 | 305.52160Price 161.34396 | +89.4% | |
| 125.395 | 237.44178Price 125.40297 | +89.4% | |
| 159.580 | 300.48225Price 159.58376 | +88.3% |
Furthest below the fair value on each stock's page, updated every day.